Name* Mobile* Select Concern* Message* Name* Mobile* Choose Treatment* Message*
1,315,316 Although there were no head-to-head RCTs comparing GLP-1 and SGLT-is for cardiovascular benefit, a meta-analysis showed no significant difference between them
Following the positive REDEFINE 1 Phase 3 data (published June 2025, PMID: 40544433), Novo Nordisk announced plans to file regulatory applications for CagriSema for obesity in the United States (FDA), European Union (EMA), and other major markets in 20252026
Frequently Asked Questions How common are headaches in the GLP-1 trial populations this article cites
standards for quality or purity, and they market these products to unknowing consumers as equivalent to branded medicines. Cardiologist Dr
Verified methods include balanced diets, consistent workout routines, and lifestyle adjustments